This company has been marked as potentially delisted and may not be actively trading. NASDAQ:LOXO Loxo Oncology (LOXO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Loxo Oncology Stock (NASDAQ:LOXO) 30 days 90 days 365 days Advanced Chart Get Loxo Oncology alerts:Sign Up Key Stats Today's Range$234.66▼$234.6650-Day Range N/A52-Week Range$101.70▼$234.93Volume400 shsAverage Volume565,561 shsMarket Capitalization$7.18 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets; strategic partnership with Illumina, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and research collaboration agreement with Veracyte, Inc. to develop medicines for patients with genetically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut. Read More Receive LOXO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Loxo Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address LOXO Stock News HeadlinesSmall Lymphocytic Lymphoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2025 | DelveInsightJuly 24, 2025 | theglobeandmail.comLoxo Oncology’s Pirtobrutinib Study: A Potential Game-Changer for CLL/SLL TreatmentJuly 16, 2025 | tipranks.comThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important updates you'll ever see. A new initiative, linked to President Trump's Executive Order #14196, has the potential to do more than just protect Social Security from collapse... According to renowned investor Louis Navellier, it could increase benefits by as much as 400%.August 2 at 2:00 AM | InvestorPlace (Ad)Is Eli Lilly and Company Stock Underperforming the Dow?May 29, 2025 | msn.comGastrointestinal Stromal Tumor Market to Grow Rapidly During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsightApril 15, 2025 | finance.yahoo.comBlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice PresidentJanuary 6, 2025 | finance.yahoo.comQ3 2024 Eli Lilly and Co Earnings CallNovember 1, 2024 | finance.yahoo.comSwitching jobs? There's more to do with your 401(k) than just rolling it overOctober 25, 2024 | msn.comSee More Headlines LOXO Stock Analysis - Frequently Asked Questions How were Loxo Oncology's earnings last quarter? Loxo Oncology Inc (NASDAQ:LOXO) released its quarterly earnings results on Thursday, August, 9th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.15. The biopharmaceutical company earned $42.60 million during the quarter, compared to the consensus estimate of $32.36 million. Loxo Oncology had a negative trailing twelve-month return on equity of 16.42% and a negative net margin of 43.49%. What other stocks do shareholders of Loxo Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Loxo Oncology investors own include Meta Platforms (META), Bristol Myers Squibb (BMY), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), GW Pharmaceuticals (GWPH) and Micron Technology (MU). Company Calendar Last Earnings8/09/2018Today8/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:LOXO CIK1581720 Webwww.loxooncology.com Phone203-653-3880FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($5.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$148.87 million Net Margins-43.49% Pretax MarginN/A Return on Equity-16.42% Return on Assets-8.66% Debt Debt-to-Equity RatioN/A Current Ratio3.62 Quick Ratio3.62 Sales & Book Value Annual Sales$21.30 million Price / Sales337.23 Cash FlowN/A Price / Cash FlowN/A Book Value$12.63 per share Price / Book18.58Miscellaneous Outstanding Shares30,610,000Free FloatN/AMarket Cap$7.18 billion OptionableOptionable Beta2.51 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:LOXO) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Loxo Oncology Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Loxo Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.